Safinamide (CAS 133865-89-1): Product Uses, Market Drivers and Supply Outlook
A market-oriented overview of safinamide uses, regulatory presence, quality expectations and Rlavie supply support.
Safinamide is a chiral active pharmaceutical ingredient used in Parkinson’s disease therapy in approved markets. Rlavie lists CAS 133865-89-1 for qualified pharmaceutical research, analytical and development requirements.
Product applications
Potential customer uses include formulation and analytical development, method verification, impurity studies, route evaluation and other controlled R&D activities. As a chiral API, safinamide also illustrates why identity, enantiomeric purity, related substances, residual solvents and solid-state considerations must be addressed together.
Market drivers
The long-term demand backdrop includes an aging population, continuing management of Parkinson’s disease and lifecycle activity across established therapies. Regulatory presence in major markets provides a verifiable foundation for development interest. Commercial opportunities will favor supply partners that can respond to project-specific specifications and documentation expectations.
Rlavie support
Rlavie can discuss intended use, specification alignment, available analytical documents, packaging and delivery requirements. Listing the compound does not mean that Rlavie supplies any marketed medicine; it means customers can approach Rlavie for a qualified material and project discussion.